Synthesis and biological characterization of protease-activated prodrugs of doxazolidine

Journal of Medicinal Chemistry

Volumn 55, Issue 14, 2012, Pages 6595-6607

  Barthel, Benjamin L ^a   Rudnicki, Daniel L ^a   Kirby, Thomas Price ^a   Colvin, Sean M ^a   Burkhart, David J ^a,b   Koch, Tad H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN B; DOXAZOLIDINE; DOXORUBICIN; PLASMIN; PRODRUG; TRYPSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CARDIOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PROTEIN DEGRADATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; DOXORUBICIN; DRUG STABILITY; HUMANS; KINETICS; OXAZOLES; PEPTIDE HYDROLASES; PHOSPHATES; PROTEOLYSIS;

EID: 84864251276     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300714p     Document Type: Article

References (54)

1. Saltiel, E.; McGuire, W. Doxorubicin (adriamycin) cardiomyopathy West. J. Med. 1983, 139, 332-341
2. Takemura, G.; Fujiwara, H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog. Cardiovasc. Dis. 2007, 49, 330-352
3. Nielsen, D.; Maare, C.; Skovsgaard, T. Cellular resistance to anthracyclines Gen. Pharmacol. 1996, 27, 251-255
4. Myers, C. E.; McGuire, W. P.; Liss, R. H.; Ifrim, I.; Grotzinger, K.; Young, R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response Science 1977, 197, 165-167
5. Siveski-Iliskovic, N.; Hill, M.; Chow, D. A.; Singal, P. K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect Circulation 1995, 91, 10-15
6. Weiss, R. B. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 1992, 19, 670-686
7. Krown, S. E.; Northfelt, D. W.; Osoba, D.; Stewart, J. S. Use of liposomal anthracyclines in Kaposi's sarcoma Semin. Oncol. 2004, 31, 36-52
8. Robert, N. J.; Vogel, C. L.; Henderson, I. C.; Sparano, J. A.; Moore, M. R.; Silverman, P.; Overmoyer, B. A.; Shapiro, C. L.; Park, J. W.; Colbern, G. T.; Winer, E. P.; Gabizon, A. A. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer Semin. Oncol. 2004, 31, 106-146
9. Lorusso, D.; Di Stefano, A.; Carone, V.; Fagotti, A.; Pisconti, S.; Scambia, G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ("hand-foot" syndrome) Ann. Oncol. 2007, 18, 1159-1164
10. Post, G. C.; Barthel, B. L.; Burkhart, D. J.; Hagadorn, J. R.; Koch, T. H. Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA J. Med. Chem. 2005, 48, 7648-7657
11. Kalet, B. T.; McBryde, M. B.; Espinosa, J. M.; Koch, T. H. Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism J. Med. Chem. 2007, 50, 4493-4500
12. Fenick, D. J.; Taatjes, D. J.; Koch, T. H. Doxoform and daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells J. Med. Chem. 1997, 40, 2452-2461
13. Burkhart, D. J.; Barthel, B. L.; Post, G. C.; Kalet, B. T.; Nafie, J. W.; Shoemaker, R. K.; Koch, T. H. Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases J. Med. Chem. 2006, 49, 7002-7012
14. Barthel, B. L.; Torres, R. C.; Hyatt, J. L.; Edwards, C. C.; Hatfield, M. J.; Potter, P. M.; Koch, T. H. Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug J. Med. Chem. 2008, 51, 298-304
15. Barthel, B. L.; Zhang, Z.; Rudnicki, D. L.; Coldren, C. D.; Polinkovsky, M.; Sun, H.; Koch, G. G.; Chan, D. C.; Koch, T. H. Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine J. Med. Chem. 2009, 52, 7678-7688
16. Cecchin, E.; Corona, G.; Masier, S.; Biason, P.; Cattarossi, G.; Frustaci, S.; Buonadonna, A.; Colussi, A.; Toffoli, G. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients Clin. Cancer Res. 2005, 11, 6901-6907
17. Duffy, M. J.; O'Grady, P.; Devaney, D.; O'Siorain, L.; Fennelly, J. J.; Lijnen, H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer Cancer Res. 1988, 48, 1348-1349
18. Giannelli, G.; Falk-Marzillier, J.; Schiraldi, O.; Stetler-Stevenson, W. G.; Quaranta, V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5 Science 1997, 277, 225-228
19. Bemis, L. T.; Schedin, P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion Cancer Res. 2000, 60, 3414-3418
20. Choong, P. F.; Nadesapillai, A. P. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis Clin. Orthop. Relat. Res. 2003, S46-58
21. Lijnen, H. R. Plasmin and matrix metalloproteinases in vascular remodeling Thromb. Haemostasis 2001, 86, 324-333
22. Ulisse, S.; Baldini, E.; Sorrenti, S.; D'Armiento, M. The urokinase plasminogen activator system: a target for anti-cancer therapy Curr. Cancer Drug Targets 2009, 9, 32-71
23. Cobos, E.; Jumper, C.; Lox, C. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer Clin. Appl. Thromb./Hemostasis 2003, 9, 241-246
24. Werle, B.; Kotzsch, M.; Lah, T. T.; Kos, J.; Gabrijelcic-Geiger, D.; Spiess, E.; Schirren, J.; Ebert, W.; Fiehn, W.; Luther, T.; Magdolen, V.; Schmitt, M.; Harbeck, N. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer Anticancer Res. 2004, 24, 4147-4161
25. D'Amico, T. A.; Brooks, K. R.; Joshi, M. B.; Conlon, D.; Herndon, J.; Petersen, R. P.; Harpole, D. H. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection Ann. Thorac. Surg. 2006, 81, 1982-1987; discussion 1987
26. De Petro, G.; Tavian, D.; Copeta, A.; Portolani, N.; Giulini, S. M.; Barlati, S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma Cancer Res. 1998, 58, 2234-2239
27. Zheng, Q.; Tang, Z. Y.; Xue, Q.; Shi, D. R.; Song, H. Y.; Tang, H. B. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor J. Cancer Res. Clin. Oncol. 2000, 126, 641-646
28. Takeuchi, Y.; Nakao, A.; Harada, A.; Nonami, T.; Fukatsu, T.; Takagi, H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study Am. J. Gastroenterol. 1993, 88, 1928-1933
29. Cantero, D.; Friess, H.; Deflorin, J.; Zimmermann, A.; Brundler, M. A.; Riesle, E.; Korc, M.; Buchler, M. W. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma Br. J. Cancer 1997, 75, 388-395
30. Shin, S. J.; Kim, K. O.; Kim, M. K.; Lee, K. H.; Hyun, M. S.; Kim, K. J.; Choi, J. H.; Song, H. S. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer Jpn. J. Clin. Oncol. 2005, 35, 342-348
31. de Groot, F. M. H.; de Bart, A. C. W.; Verheijen, J. H.; Scheeren, H. W. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin J. Med. Chem. 1999, 42, 5277-5283
32. Devy, L.; de Groot, F. H. M.; Blacher, S.; Hajitou, A.; Beusker, P.; Scheeren, W.; Foldart, J.-M.; Noel, A. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity FASEB J. 2004, 18, 565-567
33. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. A novel connector linkage applicable in prodrug design J. Med. Chem. 1981, 24, 479-480
34. Low, T. L.; Goldstein, A. L. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1 J. Biol. Chem. 1979, 254, 987-995
35. Abiko, T.; Sekino, H. Synthesis of an immunologically active fragment analog of prothymosin alpha with enhanced enzymatic stability Chem. Pharm. Bull. (Tokyo) 1991, 39, 752-756
36. Nguyen, L. T.; Chau, J. K.; Perry, N. A.; de Boer, L.; Zaat, S. A.; Vogel, H. J. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs PLoS One 2010, 5
37. Kos, J.; Werle, B.; Lah, T.; Brunner, N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer Int. J. Biol. Markers 2000, 15, 84-89
38. Jedeszko, C.; Sloane, B. F. Cysteine cathepsins in human cancer Biol. Chem. 2004, 385, 1017-1027
39. Joyce, J. A.; Baruch, A.; Chehade, K.; Meyer-Morse, N.; Giraudo, E.; Tsai, F. Y.; Greenbaum, D. C.; Hager, J. H.; Bogyo, M.; Hanahan, D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis Cancer Cell 2004, 5, 443-453
40. Dubowchik, G. M.; Firestone, R. A.; Padilla, L.; Willner, D.; Hofstead, S. J.; Mosure, K.; Knipe, J. O.; Lasch, S. J.; Trail, P. A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity Bioconjugate Chem. 2002, 13, 855-869
41. Schmid, B.; Chung, D. E.; Warnecke, A.; Fichtner, I.; Kratz, F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy Bioconjugate Chem. 2007, 18, 702-716
42. Misaka, E.; Tappel, A. L. Inhibition studies of cathepsins A, B, C and D from rat liver lysosomes Comp. Biochem. Physiol., Part B 1971, 38, 651-662
43. Hirao, T.; Hara, K.; Takahashi, K. Purification and characterization of cathepsin B from monkey skeletal muscle J. Biochem. 1984, 95, 871-879
44. Agarwal, S. K.; Choudhury, S. D.; Lamsal, M.; Khan, M. Y. Catalytic and physico-chemical characteristics of goat spleen cathepsin B Biochem. Mol. Biol. Int. 1997, 42, 1215-1226
45. Lechuga, C. G.; Hernandez-Nazara, Z. H.; Hernandez, E.; Bustamante, M.; Desierto, G.; Cotty, A.; Dharker, N.; Choe, M.; Rojkind, M. PI3K is involved in PDGF-beta receptor upregulation post-PDGF-BB treatment in mouse HSC Am. J. Physiol.: Gastrointest. Liver Physiol. 2006, 291, G1051-1061
46. Fehske, K. J.; Muller, W. E.; Wollert, U. The location of drug binding sites in human serum albumin Biochem. Pharmacol. 1981, 30, 687-692
47. Kratochwil, N. A.; Huber, W.; Muller, F.; Kansy, M.; Gerber, P. R. Predicting plasma protein binding of drugs: a new approach Biochem. Pharmacol. 2002, 64, 1355-1374
48. Koivunen, E.; Ristimaki, A.; Itkonen, O.; Osman, S.; Vuento, M.; Stenman, U. H. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix Cancer Res. 1991, 51, 2107-2112
49. Miszczuk-Jamska, B.; Merten, M.; Guy-Crotte, O.; Amouric, M.; Clemente, F.; Schoumacher, R. A.; Figarella, C. Characterization of trypsinogens 1 and 2 in two human pancreatic adenocarcinoma cell lines; CFPAC-1 and CAPAN-1 FEBS Lett. 1991, 294, 175-178
50. Yamamoto, H.; Iku, S.; Itoh, F.; Tang, X.; Hosokawa, M.; Imai, K. Association of trypsin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma Cancer 2001, 91, 1324-1331
51. Santin, A. D.; Cane, S.; Bellone, S.; Bignotti, E.; Palmieri, M.; De Las Casas, L. E.; Anfossi, S.; Roman, J. J.; O'Brien, T.; Pecorelli, S. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma Cancer 2003, 98, 1898-1904
52. Nolan, C.; Hall, L. S.; Barlow, G. H.; Tribby, I. I. E. Plasminogen activator from human embryonic kidney cell cultures. Evidence for a proactivator Biochim. Biophys. Acta 1977, 496, 384-400
53. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A.; Weber, M. J. Protease-activated "prodrugs" for cancer chemotherapy Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 2224-2228
54. Gude, M.; Ryf, J.; White, P. An accurate method for quantitation of Fmoc-derivitized solid phase supports Lett. Pept. Sci. 2002, 9, 203-206